According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

Dupixent, Adbry, and Ebglyss are FDA-approved only for the atopic dermatitis form of eczema. It is possible, however, that healthcare providers might also prescribe these medicines off-label for other ...

Read about the latest analyst upgrades and downgrades on major stocks like AMD, Skyworks, Palantir, Nike, and more in this ...

“Broken skin barriers” are real. They’re the subject of great interest from " skinfluencers " on TikTok, but they’re also ...

Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

It could see competition from Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent (dupilumab) – already a $12 billion blockbuster in other indications – as well as Sanofi’s rival oral ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...